Evidence of different mediators of central inflammation in dysfunctional and inflammatory pain - Interleukin-8 in fibromyalgia and interleukin-1 β in rheumatoid arthritis

Journal of Neuroimmunology

Volumn 280, Issue , 2015, Pages 49-55

  Kosek, Eva ^a   Altawil, Reem ^b   Kadetoff, Diana ^a   Finn, Anja ^a   Westman, Marie ^b   Le Maître, Erwan ^b   Andersson, Magnus ^a   Jensen Urstad, Mats ^b   Lampa, Jon ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cerebrospinal fluid; Chemokines; Cytokines; Fibromyalgia; Glia cells; Heart rate variability; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE; SECONDARY LYMPHOID TISSUE CHEMOKINE; TUMOR NECROSIS FACTOR; CYTOKINE;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBROMYALGIA; HEART RATE VARIABILITY; HUMAN; INFLAMMATORY PAIN; INTERLEUKIN 1BETA CEREBROSPINAL FLUID LEVEL; LOW DRUG DOSE; NERVOUS SYSTEM INFLAMMATION; PARASYMPATHETIC TONE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; RHEUMATOID ARTHRITIS; SYMPATHETIC TONE; AUTONOMIC NERVOUS SYSTEM; BLOOD; CEREBROSPINAL FLUID; HEART RATE; LUMBAR PUNCTURE; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PAIN; PAIN MEASUREMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIOIMMUNOASSAY;

ADULT; ARTHRITIS, RHEUMATOID; AUTONOMIC NERVOUS SYSTEM; CYTOKINES; FEMALE; FIBROMYALGIA; HEART RATE; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-8; MIDDLE AGED; PAIN; PAIN MEASUREMENT; RADIOIMMUNOASSAY; SPINAL PUNCTURE; STATISTICS, NONPARAMETRIC;

EID: 84924769578     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2015.02.002     Document Type: Article

References (72)

1. Ahn D.K., Lee K.R., Lee H.J., Kim S.K., Choi H.S., Lim E.J., Park J.S. Intracisternal administration of chemokines facilitated formalin-induced behavioral responses in the orofacial area of freely moving rats. Brain Res. Bull. 2005, 66:50-58.
2. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., Birnbaum N.S., Burmester G.R., Bykerk V.P., Cohen M.D., Combe B., Costenbader K.H., Dougados M., Emery P., Ferraccioli G., Hazes J.M., Hobbs K., Huizinga T.W., Kavanaugh A., Kay J., Kvien T.K., Laing T., Mease P., Ménard H.A., Moreland L.W., Naden R.L., Pincus T., Smolen J.S., Stanislawska-Biernat E., Symmons D., Tak P.P., Upchurch K.S., Vencovský J., Wolfe F., Hawker G. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010, 62:2569-2581.
3. Arendt-Nielsen L., Nie H., Laursen M.B., Laursen B.S., Madeleine P., Simonsen O.H., Graven-Nielsen T. Sensitization in patients with painful knee osteoarthritis. Pain 2010, 149:573-581.
4. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., Healey L.A., Kaplan S.R., Liang M.H., Luthra H.S., MedsgerJR T.A., Mitchell D.M., Neustadt D.H., Pinals R.S., Schaller J.G., Sharp J.T., Wilder R.L., Hunder G.G. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthrtitis. Arthritis Rheum. 1988, 3:315-324.
5. Backonja M., Coe C.L., Muller D.A., Schell K. Altered cytokine levels in the blood and cerebrospinal fluid of chronic pain patients. J. Neuroimmunol. 2008, 195:157-163.
6. Banks W.A., Kastin A.J., Broadwell R.D. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 1995, 2:241-248.
7. Bartfai T. Telling the brain about pain. Nature 2001, 410:425-427.
8. Bazzichi L., Rossi A., Massimetti G., Giannaccini G., Giuliano T., Feo F.D., Ciapparelli A., Dell'Osso L., Bombardieri S. Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. Clin. Exp. Rheumatol. 2007, 25:225-230.
9. Buysse D., Reynolds I., Monk C., Kupfer D. The Pittsburg Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989, 28:193-213.
10. Carville S., Arendt-Nielsen L., Bliddal H., Blotman F., Branco J., Buskila D., DaSilva J., Danneskiøld-Samsøe B., Dincer F., Henriksson C., Henriksson K., Kosek E., Longley K., McCarthy G., Perrot S., Puszczewicz M., Sarzi-Puttini P., Silman A., Späth M., Choy E. EULAR evidence based recommendations for the management of fibromyalgia syndrome. Ann. Rheum. Dis. 2008, 67:536-541.
11. Chen P., Shibata M., Zidovetzki R., Fisher M., Zlokovic B.V., Hofman F.M. Endothelin-1 and monocyte chemoattractant protein-1 modulation in ischemia and human brain-derived endothelial cell cultures. J. Neuroimmunol. 2001, 116:62-73.
12. Chen D.-Y., Chen Y.-M., Chen H.-H., Hsieh C.-W., Lin C.-C., Lan J.-L. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-a therapy. Arthritis Res. Ther. 2011, 13:R126.
13. Contopoulos-Ioannidis D., Karvouni A., Kouri I., Ioannidis J. Reporting and interpretation of SF-36 outcomes in randomised trials: systematic review. BMJ 2009, 339:3006.
14. Cunha F.Q., Lorenzetti B.B., Poole S., Ferreira S.H. Interleukin-8 as a mediator of sympathetic pain. Br. J. Pharmacol. 1991, 104:765-767.
15. Cunha T.M., Verri W.A., Silva J.S., Poole S., Cunha F.Q., Ferreira S.H. A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. PNAS 2005, 102:1755-1760.
16. Eklund K.K., Leirisalo-Repo M., Ranta P., Mäki T., Kautiainen H., Hannonen P., Korpela M., Hakala M., Järvinen P., Möttönen T. Serum IL-1β levels are associated with the presence of erosions in recent onset rheumatoid arthritis. Clin. Exp. Rheumatol. 2007, 25:684-689. for the FIN-RACo Trial Group.
17. Feldmann M., Maini R.N. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol. Rev. 2008, 223:7-19.
18. Gao Y.-J., Ji R.-R. Targeting astrocyte signaling for chronic pain. Neurotherapeutics 2010, 7:482-493.
19. Guo W., Wang H., Watanabe M., Shimizu K., Zou S., LaGraize S.C., Wei F., Dubner R., Ren K. Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain. J. Neurosci. 2007, 27:6006-6018.
20. Gur A., Karakoc M., Nas K., Cevik R., Denli A., Sarac J. Cytokines and depression in cases with fibromyalgia. J. Rheumatol. 2002, 29:358-361.
21. Gutierrez E.G.B.W., Kastin A.J. Murine tumor necrosis factor alpha is transported from blood to brain in the mouse. J. Neuroimmunol. 1993, 47:169-176.
22. Gwilym S.E., Keltner J.R., Warnaby C.E., Carr A.J., Chizh B., Chessell I., Tracey I. Psychophysical and functional imaging evidence supporting the presence of central sensitization in a cohort of osteoarthritis patients. Arthritis Rheum. 2009, 61:1226-1234.
23. Holman A.J., Ng E. Heart rate variability predicts anti-tumour necrosis factor therapy response for inflammatory arthritis. Auton. Neurosci. 2008, 143:58-67.
24. Janse Van Rensburg D.C., Ker J.A., Grant C.C., Fletcher L. Autonomic impairment in rheumatoid arthritis. Int. J. Rheum. Dis. 2012, 15:419-426.
25. Kadetoff D., Lampa J., Westman M., Andersson M., Kosek E. Evidence of central inflammation in fibromyalgia - increased cerebrospinal fluid interleukin-8 levels. J. Neuroimmunol. 2012, 242:33-38.
26. Keyszer G., Langer T., Kornhuber M., Taute B., Horneff G. Neurovascular mechanisms as a possible cause of remission of rheumatoid arthritis in hemiparetic limbs. Ann. Rheum. Dis. 2004, 63:1349-1351.
27. Kosek E., Ordeberg G. Lack of pressure pain modulation by heterotopic noxious conditioning stimulation in patients with painful osteoarthritis before, but not following, surgical pain relief. Pain 2000, 88:69-78.
28. Kosek E., Ordeberg G. Abnormalities of somatosensory perception in patients with painful osteoarthritis normalize following successful treatment. Eur. J. Pain 2000, 4:229-238.
29. Kosek E., Ekholm J., Hansson P. Sensory dysfunction in fibromyalgia patients with implications for pathogenic mechanisms. Pain 1996, 68:375-383.
30. Kotani N., Kudo R., Sakurai Y., Sawamura D., Sessler D.I., Okada H., Nakayama H., Yamagata T., Yasujima M., Matsuki A. Cerebrospinal fluid interleukin 8 concentrations and the subsequent development of postherpetic neuralgia. Am. J. Med. 2004, 116:318-324.
31. Lampa J., Westman M., Kadetoff D., Nordenstedt Agréus A., Le Maître E., Gilllis-Haegerstrand C., Andersson M., Khademi M., Corr M., Christianson C.A., Delaney A., Yaksh T.L., Kosek E., Svensson C.I. Peripheral inflammatory disease associated with centrally activated IL-1 system in humans and mice. PNAS 2012, 109:12728-12733.
32. Leffler A.S., Kosek E., Lerndal T., Nordmark B., Hansson P. Somatosensory perception and function of diffuse noxious inhibitory controls (DNIC) in patients suffering from rheumatoid arthritis. Eur. J. Pain 2002, 6:161-176.
33. Li H.Y., Ericsson A., Sawchenko P.E. Distinct mechanisms underlie activation of hypothalamic neurosecretory neurons and their medullary catecholaminergic afferents in categorically different stress paradigms. PNAS 1996, 19:2359-2364.
34. Lin J.-M., Brimmer D., Maloney E., Nyarko E., BeLue R., Reeves W. Further validation of the Multidimensional Fatigue Inventory in a US adult population sample. Popul. Health Metrics 2009, 7:18.
35. Lundborg C., Hahn-Zoric M., Biber B., Hansson E. Glial cell line-derived neurotrophic factor is increased in cerebrospinal fluid but decreased in blood during long-term pain. J. Neuroimmunol. 2010, 220:108-113.
36. Madhok R., Crilly A., Watson J., Capell H.A. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann. Rheum. Dis. 1993, 52:232-234.
37. Malik M., The Task Force of the European Society of Cardiology, The North American Society of Pacing and Electrophysiology Heart rate variability; standards of measurement, physiological interpretation, and clinical use. Eur. Heart J. 1996, 17:354-381.
38. Martinez-Lavin M. Biology and therapy of fibromyalgia: stress, the stress response system, and fibromyalgia. Arthritis Res. Ther. 2007, 9:216.
39. Matsumoto K., Koike K., Miyake A., Watanabe K., Konishi K., Kiyama H. Noxious stimulation enhances release of cytokine-induced neutrophil chemoattractant from hypothalamic neurosecretory cells. Neurosci. Res. 1997, 27:181-184.
40. Meeus M., Goubert D., DeBacker F., Struyf F., Hermans L., Coppieters I., DeWandele I., DaSilva H., Calders P. Heart rate variability in patients with fibromyalgia and patients with chronic fatigue syndrome: a systematic review. Semin. Arthritis Rheum. 2013, 43:279-287.
41. Milligan E., Watkins L. Pathological and protective roles of glia in chronic pain. Nat. Rev. Neurosci. 2009, 10:23-36.
42. Nam J.L., Winthrop K.L., Vollenhoven RFv, Pavelka K., Valesini G., Hensor E.M.A., Worthy G., Landewé R., Smolen J.S., Emery P., Buch M.H. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann. Rheum. Dis. 2010, 69:976-986.
43. Neurath M.F., Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev. 2011, 22:83-89.
44. Nishimoto N., Yoshizaki K., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., Hashimoto J., Azuma J., Kishimoto T. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody. A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004, 50:1761-1769.
45. Nishimoto N., Hashimoto J., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., Murata N., VanDerHeijde D., Kishimoto T. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann. Rheum. Dis. 2007, 66:1162-1167.
46. Oh S.B., Tran P.B., Gillard S.E., Hurley R.W., Hammond D.L., Miller R.J. Chemokines and glycoprotein120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J. Neurosci. 2001, 21:5027-5035.
47. Ortega E., García J.J., Bote M.E., Martín-Cordero L., Escalante Y., Saavedra J.M., Northoff H., Giraldo E. Exercise in fibromyalgia and related inflammatory disorders: known effects and unknown chances. Exerc. Immunol. Rev. 2009, 15:42-65.
48. Pavlov V.A., Ochani M., Gallowitsch-Puerta M., Ochani K., Huston J.M., Czura C.J., Al-Abed Y., Tracey K.J. Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia. PNAS 2006, 103:5219-5223.
49. Pinteaux E., Parker L.C., Rothwell N.J., Luheshi G.N. Expression of interleukin-1 receptors and their role in interleukin-1 actions in murine microglial cells. J. Neurochem. 2002, 83:754-763.
50. Quan N., Herkenham M. Connecting cytokines and brain: a review of current issues. Histol. Histopathol. 2002, 17:273-288.
51. Reijerkerk A., Lakeman K.A., Drexhage J.A., VanHetHof B., VanWijck Y., VanderPol S.M., Kooij G., Geerts D., DeVries H.E. Brain endothelin barrier passage by monocytes is controlled by the endothelin system. J. Neurochem. 2012, 121:730-737.
52. Sachs D., Cunha F.Q., Poole S., Ferreira S.H. Tumour necrosis factor-a, interleukin-1b and interleukin-8 induce persistent mechanical nociceptor hypersensitivity. Pain 2002, 96:89-97.
53. Sakamoto Y., Koike K., Kiyama H., Konishi K., Watanabe K., Tsurufuji S., Bicknell R.J., Hirota K., Miyake A. A stress-sensitive chemokinergic neuronal pathway in the hypothalamo-pituitary system. Neuroscience 1996, 75:133-142.
54. Samad T.A., Moore K.A., Sapirstein A., Billet S., Allchorne A., Poole S., Bonventrek J.V., Woolf C.J. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001, 410:471-475.
55. Sandrone G., Mortara A., Torzillo D., LaRovere M.T., Malliani A., Lombardi F. Effects of beta blockers (atenolol or metoprolol) on heart rate variability after acute myocardial infarction. Am. J. Cardiol. 1994, 74:340-345.
56. Schliebs R., Heidel K., Apelt J., Gniezdzinska M., Kirazov L., Szutowicz A. Interaction of interleukin 1-beta with muscarinic acetylcholine-mediated signaling cascade in cholinergically differentiated SH-SY5Y cells. Brain Res. 2006, 1122:78-85.
57. Schmidt-Wilcke T., Clauw D.J. Fibromyalgia: from pathophysiology to therapy. Nat. Rev. Rheumatol. 2011, 7:518-527.
58. Shi S., Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur. J. Clin. Pharmacol. 2008, 64:233-252.
59. Sofroniew M.V., Howe C.L., Mobley W.C. Nerve growth factor signaling, neuroprotection, and neural repair. Annu. Rev. Neurosci. 2001, 24:1217-1281.
60. Szelenyi J. Cytokines and the central nervous system. Brain Res. Bull. 2001, 54:329-338.
61. Szelenyi J., Vizi E.S. The catecholamine-cytokine balance interaction between the brain and the immune system. Ann. N. Y. Acad. Sci. 2007, 1113:311-324.
62. Tracey K.J. Physiology and immunology of the cholinergic anti-inflammatory pathway. J. Clin. Invest. 2007, 117:289-296.
63. Verri W.A., Cunha T.M., Parada C.A., Poole S., Cunha F.Q., Ferreira S.H. Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development?. Pharmacol. Ther. 2006, 112:116-138.
64. Vladic A., Horvat G., Vukadin S., Sucic Z., Simaga S. Cerebrospinal fluid and serum protein levels if tumour necrosis factor-alpha (THF-alpha), interleukin-6 (IL-6) and soluble interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6 gp80) in multiple sclerosis patients. Cytokine Growth Factor Rev. 2002, 20:86-89.
65. von Känel R., Nelesen R.A., Mills P.J., Ziegler M.G., Dimsdale J.E. Relationship between heart rate variability, interleukin-6, and soluble tissue factor in healthy subjects. Brain Behav. Immun. 2008, 22:461-468.
66. Wallace D., Linker-Israeli M., Hallegua D., Silverman S., Silver D., Weisman M. Cytikines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology 2001, 40:743-749.
67. Wang H., Buchner M., Moser M.T., Daniel V., Schiltenwolf M. The role of IL-8 in patients with fibromyalgia. A prospective longitudinal study of 6months. Clin. J. Pain 2009, 25:1-4.
68. Watkins L.R., Maier S.F. Immune regulation of central nervous system functions: from sickness responses to pathological pain. J. Int. Med. 2005, 257:139-155.
69. Watkins L.R., Maier S.F., Goehler L.E. Cytokine-to-brain communication: a review & analysis of alternative mechanisms. Life Sci. 1995, 57:1011-1026.
70. Wolfe F., Smythe H.A., Yunus M.B., Bennett R.M., Bombardier C., Goldenberg D.L., Tugwell P., Cambell S.M., Abeles M., Clark P., Gatter A.G., Hamaty D., Lessard J., Lichtbroun A.S., Masi A.T., McCain G.A., Reynolds W.J., Romano T.J., Russell I.J., Sheon R.P. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum. 1990, 33:160-172.
71. Yamamoto J., Nishiyori A., Takami S., Ohtani Y., Minami M., Satoh M. A hyperalgesic effect of intracerebroventricular cytokine-induced neutrophil chemoattractant-1 in the rat paw pressure test. Eur. J. Pharmacol. 1998, 363:131-133.
72. Zidovetzki R., Chen P., Chen M., Hofman F.M. Endothelin-1-induced interleukin-8 production in human brain-derived endothelial cells is mediated by the protein kinase C and protein tyrosine kinase pathways. Blood 1999, 94:1291-1299.